Image Sourced ShutterStock
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • CardieX has successfully launched its blood pressure monitors in China
  • Earn up to $50 million a year from sales of the device

CardieX Limited has announced the process has been made regarding its China growth strategy by establishing business operations and a marketing presence in Beijing and Shanghai.

The launch of operations follows Chinese approval of the Oscar 2 SphygmoCor Inside ambulatory blood pressure monitor, a product developed between CardieX group company AtCor Medical and US blood pressure monitor manufacturer SunTech Medical.

The SphygmoCor technology is used for central arterial pressure waveform analysis to better inform on blood pressure and management. The system helps physicians individualise care for patients with a range of diseases such as hypertension, renal disease, diabetes and heart failure.

It provides measures of the central arterial pressure waveform and pulse wave velocity as well as an assessment of arterial stiffness via waveform analysis.

This approval will allow for SphygmoCor to be utilised by over 20,000 physicians, hospitals and clinics throughout China. Blood pressure monitoring is the most effective method of detecting, diagnosing, monitoring and managing hypertension in China, which is one of the most common health disorders.

The launch of Oscar 2 builds on the recent milestones with CardieX’s group inHealth’s telehealth solutions to be deployed across China’s third-largest telemedicine platform Health160 which has over 167 million users.

The pilot program is currently in its first phase of a significant commercial opportunity with the successful pilot to lead to the formalisation of a long-term partnership.

CardieX and inHealth are also looking to further their technology into telehealth solutions and home health devices throughout China.

CDX by the numbers
More From The Market Herald

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…